IP Library Granted Patent US 7,138,496
Granted Patent B2
US 7,138,496 · App. 10/360,828 · Granted Nov 21, 2006

Human monoclonal antibodies against human CXCR4

Assignee: Genetastix Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,138,496
App. No.
10/360,828
Granted
Nov 21, 2006
Kind
B2
Abstract

Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors.

Claims (5)

1. An isolated antibody that specifically binds to human CXCR4, wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 60 and a light chain variable region of SEQ ID NO: 61, or a heavy chain variable region of SEQ ID NO: 63 and a light chain variable region of SEQ ID NO: 64.

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody of claim 2 , wherein the monoclonal antibody is a single chain antibody.

4. The antibody of claim 3 , wherein the single chain antibody is encoded by DNA SEQ ID NO: 59 or 62.

5. The antibody of claim 1 , wherein the antibody specifically binds to loop 6 of human CXCR4 of SEQ ID NO: 58.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2006
From: HUA, SHAOBING; PAULING, MICHELLE HAYNES; ZHU, LI
To: GENETASTIX CORPORATION
Reel/Frame 018314/0478 →
Continuity (4)
Continuation In Part 1013397800 · Apr 25, 2002
Continuation In Part 1007230100 · Feb 8, 2002
Continuation In Part 1007186600 · Feb 8, 2002
Related Publication 20030206909A1 · Nov 6, 2003